Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation
Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 4
2.1 High Unmet Need and a Limited Number of Marketed Options 4
2.2 Large, Diverse and Highly Innovative Pipeline 4
2.3 Active Deals Landscape Reflects the Dynamic Pipeline 4
3 The Case for Innovation 5
3.1 Growing Opportunities for Biologic Products 6
3.2 Diversification of Molecular Targets 6
3.3 Innovative First-in-Class Product Developments Remain Attractive 7
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7
3.5 Sustained Innovation 8
3.6 GBI Research Report Guidance 8
4 Clinical and Commercial Landscape 9
4.1 Disease Overview 9
4.2 Symptoms 9
4.3 Diagnosis 10
4.3.1 Clinical Presentation 10
4.3.2 Alpha-Fetoprotein 10
4.3.3 Diagnostic Imaging and Scans 10
4.3.4 Screening 10
4.3.5 Biopsy 11
4.3.6 Staging, Classification and Prognosis 11
4.4 Epidemiology and Etiology 11
4.5 Pathophysiology 13
4.6 Risk Factors and Co-Morbidities 17
4.7 Treatment Options 17
4.8 Treatment Algorithm 18
4.9 Overview of Marketed Products for Liver Cancer 19
4.9.1 Innovative Products in the Liver Cancer Market 20
4.9.2 Unmet Needs 21
5 Assessment of Pipeline Product Innovation 22
5.1 Liver Cancer Pipeline by Molecule Type, Phase and Therapeutic Target 22
5.2 Comparative Distribution of Programs between the Liver Cancer Market and Pipeline by Therapeutic Target Family 26
5.3 First-in-Class Pipeline Programs 26
6 Signaling Network, Disease Causation and Innovation Alignment 34
6.1 The Complexity of Signaling Networks in Oncology 34
6.2 Signaling Pathways Disease-Causing Mutations and First-in-Class Molecular Target Integration 35
6.3 First-in-Class Target Matrix Assessment 35
7 First-in-Class Target Evaluation 38
7.1 Pipeline Programs Targeting PIK3CA, PIK3CB and PIK3CG 38
7.2 Pipeline Programs Targeting Protein Kinase C Delta 39
7.3 Pipeline Programs Targeting AKT1 40
7.4 Pipeline Programs Targeting HER3/ERBB3 42
7.5 Pipeline Programs Targeting ROR1 43
7.6 Pipeline Programs Targeting PRKACA fusions 44
7.7 Pipeline Programs Targeting Frizzled 2 44
7.8 Pipeline Programs Targeting CDK1 and 2 45
7.9 Pipeline Programs Targeting PTK2/FAK 46
7.10 Conclusion 47
8 Deals and Strategic Consolidations 48
8.1 Industry-Wide First-in-Class Deals 48
8.2 Liver Cancer Deals Landscape 49
8.3 Licensing Deals 50
8.3.1 Molecule Type 52
8.3.2 Molecular Target 52
8.4 Co-development Deals 55
8.4.1 Molecule Type 56
8.4.2 Molecular Target 56
8.5 First-in-Class Programs Not Involved in Licensing or Co-development Deals 58
9 Appendix 64
9.1 Abbreviations 64
9.2 References 65
9.3 Research Methodology 68
9.4 Secondary Research 69
9.4.1 Market Analysis 69
9.4.2 Pipeline Analysis 69
9.4.3 First-in-Class Matrix Assessment 69
9.4.4 First-in-Class Target Profiles 70
9.4.5 Licensing and Co-development Deals 70
9.5 Contact Us 70
9.6 Disclaimer 70
List of Tables
Table 1: Symptoms of Liver Cancer 10
Table 2: Tumor, Regional Lymph Node and Metastasis Staging 11
Table 3: Risk Factors and Comorbidities for Liver Cancer 17
Table 4: Liver Cancer, Key Features and Pipeline Activity of PIK3CA/PIK3CB/PIK3CG 39
Table 5: Liver Cancer Key Features and Pipeline Activity of PRCKD 40
Table 6: Liver Cancer, Key Features and Pipeline Activity of AKT1 42
Table 7: Liver Cancer, Key Features and Pipeline Activity of HER3 43
Table 8: Liver Cancer, Key Features and Pipeline Activity of ROR1 43
Table 9: Liver Cancer, Key Features and Pipeline Activity of PRKACA Fusions 44
Table 10: Liver Cancer, Key Features and Pipeline Activity of FZD2 45
Table 11: Liver Cancer, Key Features and Pipeline Activity of CDK1/2 46
Table 12: Liver Cancer, Key Features and Pipeline Activity of PTK2/FAK 47
List of Figures
Figure 1: Innovation Trends in Product Approvals, Number of Product Approvals by FDA and Five-Year Moving Average of Products Approvals (%), 1987-2015 6
Figure 2: Sales Performance After Marketing Approval of First-in-Class and Non-First-in-Class Products, 2006-2013 ($m) 7
Figure 3: Liver Cancer, Marketed Product Overview, 2017 19
Figure 4: Liver Cancer, Pipeline Products by Therapy Area, 2017 22
Figure 5: Liver Cancer, Developmental Pipeline Overview, 2017 23
Figure 6: Liver Cancer, Developmental Pipeline Overview, 2017 25
Figure 7: Liver Cancer, Molecular Target Category Comparison, Pipeline and Marketed Products, 2017 26
Figure 8: Liver Cancer Drug Market, Global, Percentage Distribution of First-in-Class Products in Pipeline by Stage of Development (%), 2017 27
Figure 9: Liver Cancer Drug Market, Global, Distribution of First-in-Class Products in Pipeline by Molecular Target (%), 2017 27
Figure 10: Liver Cancer, Products in the Pipeline (Part 1), 2017 28
Figure 11: Liver Cancer, Products in the Pipeline Part 2, 2017 29
Figure 12: Liver Cancer, Products in the Pipeline Part 3, 2017 30
Figure 13: Liver Cancer, Products in the Pipeline Part 4, 2017 31
Figure 14: Liver Cancer, Products in the Pipeline Part 5, 2017 32
Figure 15: Liver Cancer, Products in the Pipeline Part 6, 2017 33
Figure 16: Liver Cancer, First-in-Class Molecular Target Analysis Matrix, Part 1 2017 36
Figure 17: Liver Cancer, First-in-Class Molecular Target Analysis Matrix, Part 2 2017 37
Figure 18: Liver Cancer, First-in-Class Molecular Target Analysis Matrix, Part 3 2017 37
Figure 19: Liver Cancer, PIK3CA/PIK3CB/PIK3CG Targeting Products, 2017 39
Figure 20: Liver Cancer, PRKCD Targeting Products 40
Figure 21: Liver Cancer, AKT1 Targeting Products, 2017 41
Figure 22: Liver Cancer, HER3 Targeting Products, 2017 42
Figure 23: Liver Cancer, ROR1 Targeting Products, 2017 43
Figure 24: Liver Cancer, PRKACA Fusion Targeting Products, 2017 44
Figure 25: Liver Cancer, FZD2 Targeting Products, 2017 45
Figure 26: Liver Cancer, CDK1/2 Targeting Products, 2017 46
Figure 27: Liver Cancer, PTK2/FAK Targeting Products, 2017 47
Figure 28: Pharmaceutical Market, Global, Industry-Wide Deals by Stage of Development, 2006-2014 48
Figure 29: Pharmaceutical Market, Global, Industry Licensing Deal Values by Stage of Development, 2006-2014 49
Figure 30: Liver Cancer, Global, Licensing Deals by Region and Value, 2006-Q1 2017 51
Figure 31: Liver Cancer, Global, Licensing Deals by Stage and Value, 2006-Q1 2017 52
Figure 32: Liver Cancer, Licensing Deals by Molecular Type, 2006-Q1 2017 52
Figure 33: Liver Cancer, Licensing Deals by Molecular Target, 2006-Q1 2017 53
Figure 34: Liver Cancer, Licensing Deals with Disclosed Values, 2006-Q1 2017 54
Figure 35: Liver Cancer Drug Market, Global, Co-development Deals by Region, Value and Year, 2006-Q1 2017 55
Figure 36: Liver Cancer, Co-development Deals by Stage and Value, 2006-Q1 2017 56
Figure 37: Liver Cancer, Co-development Deals by Molecule Type, 2006-Q1 2017 56
Figure 38: Liver Cancer, Co-development Deals by Molecular Target, 2006-Q1 2017 57
Figure 39: Liver Cancer, Co-development Deals with Disclosed Values, 2006-Q1 2017 57
Figure 40: Liver Cancer Market, Global, Pipeline Programs in Active Development Involved in Previous Deals, 2017 58
Figure 41: Liver Cancer Market, Global, Pipeline Programs in Active Development Without Recorded Prior Deal Involvement, 2016 (Part 1) 59
Figure 42: Liver Cancer Market, Global, Pipeline Programs in Active Development Without Recorded Prior Deal Involvement, 2016 (Part 2) 60
Figure 43: Liver Cancer Market, Global, Pipeline Programs in Active Development Without Recorded Prior Deal Involvement, 2016 (Part 3) 61
Figure 44: Liver Cancer Market, Global, Pipeline Programs in Active Development Without Recorded Prior Deal Involvement, 2016 (Part 4) 62
Figure 45: Liver Cancer Market, Global, Pipeline Programs in Active Development Without Recorded Prior Deal Involvement, 2016 (Part 5) 63
Global Small Cell Lung Cancer Therapeutics Market Size, Status and Forecast 2019-2025
Published: 17-Jul-2019 Price: US 3900 Onwards Pages: 105
Lung cancer can be categorized into two types: non-small cell lung cancer and small cell lung cancer. Small cell lung cancer constitutes roughly 10-15 percent of all diagnosed cases of lung cancer. Small cell lung cancer is categorized into two types: small cell carcinoma and combined small cell carcinoma. It can be further classified into two stages: limited-stage small cell lung cancer and extensive-stage small cell lung cancer. Small cell lung cancer is caused by smoking tobacco, or second ha......
Global Immuno-Oncology Market Size, Status and Forecast 2019-2025
Published: 17-Jul-2019 Price: US 3900 Onwards Pages: 106
Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.
In 2018, the global Immuno-Oncology market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Immuno-Oncology status, future forecast, growth opportunity, ke......
Global Non-Melanoma Skin Cancer Market Size, Status and Forecast 2019-2025
Published: 17-Jul-2019 Price: US 3900 Onwards Pages: 109
Non-melanoma skin cancer is usually treated as a simple lesion in the initial stages but if not treated properly, it can quickly mushroom and spread to other body parts.
Radiation therapy has a market share approaching 88% in the non-melanoma skin cancer treatment market in 2017 itself and is unlikely to cede this commanding position anytime soon.
In 2018, the global Non-Melanoma Skin Cancer market size was xx million US$ and it is expected to reach xx million US$ by the end of 202......
Global Cancer Gene Therapy Market Size, Status and Forecast 2019-2025
Published: 16-Jul-2019 Price: US 3900 Onwards Pages: 99
Cancer could be defined as uncontrolled cell growth in the body leading to organ malfunction. If untreated, it can lead to death. Uncontrolled growth of cell is managed by the body in several ways, one of them is by deploying white blood cells to detect and eradicate these cancerous cells. It has been discovered that the immune system could be manipulated to influence cancerous cells to destroy itself.
Several unmet medical needs for treatment of cancer have encouraged R&D of cancer gene ......
Global Breast Cancer Monoclonal Antibodies Market Size, Status and Forecast 2019-2025
Published: 16-Jul-2019 Price: US 3900 Onwards Pages: 101
Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protein stimulates the growth and division of malignant cells.
The breast cancer monoclonal antibodies (mAbs) market is one of the fastest-growing segments of the global mAbs market and has gained ma......
Global Ovarian Cancer Therapeutics Market Size, Status and Forecast 2019-2025
Published: 15-Jul-2019 Price: US 3900 Onwards Pages: 98
Ovarian cancer, and its rising incidence rate, is a growing concern worldwide. Market players that are currently engaged in the development of drugs and therapies for ovarian cancer stand to benefit by observing the latest trends and pipeline competitor products.
In 2018, the global Ovarian Cancer Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global O......
Global Bladder Cancer Therapeutics Market Size, Status and Forecast 2019-2025
Published: 15-Jul-2019 Price: US 3900 Onwards Pages: 98
The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the innermost layer called urothelium or transitional epithelium, composed of epithelium or transitional cells.
The availability of targeted therapy will be one of the major factors driving the growth p......
Global Castration Resistant Prostate Cancer Treatment Market Size, Status and Forecast 2019-2025
Published: 12-Jul-2019 Price: US 3900 Onwards Pages: 96
Prostate cancer can be defined as it is a form of cancer that develops into male reproductive system. Most of the prostate cancer are slow growing and stable but sometimes it can spread from prostate (gland) to other part of body such as bone and lymph node. Initially prostate cancer does not pose any symptom but in severe cases it can cause pain during urination and can cause problem during sexual intercourse. Castration resistant prostate cancer is referred to as a prostate cancer that is spre......
Global Gene Therapy for Ovarian Cancer Market Size, Status and Forecast 2019-2025
Published: 12-Jul-2019 Price: US 3900 Onwards Pages: 98
Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor, and stromal ovarian tumor are some of the less common types. It is the seventh most common cancer in women globally and 18th most common cancer overall. The ovarian cancer immunotherapies market has......
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details - email@example.com
/ +1 888 391 5441 )
- Ad Hoc
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs